A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms MIRACLE
- 18 Dec 2017 Planned End Date changed from 1 Jan 2016 to NULL.
- 15 Sep 2017 Status changed to completed.
- 18 Feb 2015 New trial record